Literature DB >> 30908816

Fetal cardiac findings and hemodynamic changes associated with severe lower urinary tract obstruction in utero.

J Cohen1, S Levasseur1, L Simpson2, R Miller2, L Freud1.   

Abstract

OBJECTIVES: To describe fetal echocardiographic findings associated with lower urinary tract obstruction (LUTO) and to compare anatomic and hemodynamic measurements between fetuses with LUTO and gestational age (GA)-matched controls, with an emphasis on quantitative indices of diastolic function and cardiac output.
METHODS: This was a retrospective cohort study of fetuses diagnosed with severe LUTO with giant bladder, which underwent at least one fetal echocardiogram at our center between January 2005 and June 2018. Fetuses with major congenital heart disease were excluded. Control fetuses did not have any structural or functional abnormalities and were GA-matched to the LUTO fetuses based on the time of the first fetal echocardiogram. Cardiac anatomy and hemodynamic measurements were compared between fetuses with LUTO and controls. In infants with LUTO, serial fetal and postnatal echocardiographic data were assessed, when available, and clinical outcomes were reviewed.
RESULTS: Twenty-six fetuses with LUTO and at least one fetal echocardiogram available were identified, one of which was excluded due to hypoplastic left heart syndrome, leaving 25 LUTO fetuses in the final cohort. The mean GA at the first fetal echocardiogram was 25.4 ± 5.1 weeks in the LUTO group and 25.3 ± 5.0 weeks in the control group. Common findings in fetuses with LUTO included cardiomegaly (40%), pericardial effusion (44%), right ventricular (RV) hypertrophy (64%) and left ventricular (LV) hypertrophy (48%). Compared with GA-matched controls, LUTO fetuses had lower ascending aorta Z-score (-0.10 ± 0.94 vs -0.93 ± 1.03; P = 0.02) and aortic isthmus Z-score (-0.14 ± 0.86 vs -1.62 ± 1.11; P < 0.001), shorter mitral valve inflow time indexed to cardiac cycle length (0.46 ± 0.04 vs 0.41 ± 0.06; P = 0.002), and worse (increased) LV myocardial performance index (0.39 ± 0.03 vs 0.44 ± 0.04; P < 0.001). In addition, the ratio of RV to LV cardiac index was higher in LUTO fetuses compared with controls (1.62 ± 0.13 vs 1.33 ± 0.11; P < 0.001). Of the 25 LUTO pregnancies, two were lost to follow-up, three underwent elective termination of pregnancy and three ended in intrauterine fetal demise. Four (16%) patients had mildly hypoplastic left-heart structures, comprising two with aortic arch hypoplasia and two with mitral and aortic stenosis.
CONCLUSION: In addition to presenting with cardiomegaly, pericardial effusion and ventricular hypertrophy, fetuses with LUTO demonstrate LV diastolic dysfunction and appear to redistribute cardiac output as compared to control fetuses, which may contribute to the development of left-heart hypoplasia.
Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  altered hemodynamics; fetal echocardiogram; left heart hypoplasia; lower urinary tract obstruction

Mesh:

Year:  2019        PMID: 30908816     DOI: 10.1002/uog.20271

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  2 in total

1.  Reference ranges of fetal heart function using a Modified Myocardial Performance Index: a prospective multicentre, cross-sectional study.

Authors:  Lijuan Sun; Jingjing Wang; Xiaoting Su; Xinlin Chen; Yuqing Zhou; Xiaoming Zhang; Hong Lu; Jianmei Niu; Lan Yu; Congxin Sun; Wenjun Zhang; Jijing Han; Lina Zhang; Zhenna Wang; Peiwen Chen; Tiantian Chen; Hua Hong; Lulu Zhou; Baoying Ye; Wei Guo; Wei Zhao; Na Zhang; Zhen Li; Sheng Zhao; Qingqing Wu; Jiawei Tian; Yuxin Jiang
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

2.  Decreased biventricular myocardial deformation in fetuses with lower urinary tract obstruction.

Authors:  Ran Xu; Jiawei Zhou; Qichang Zhou; Shi Zeng
Journal:  BMC Pregnancy Childbirth       Date:  2020-08-12       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.